IQVIA Strengthens Early-Stage Discovery Research with Advanced In Vitro and AI-Driven Solutions
Why is the life sciences industry facing a critical need for accelerated drug discovery? IQVIA Holdings Inc. a global leader in advanced analytics, technology solutions, and clinical research services, has announced a strategic acquisition of certain discovery services assets from Charles River Laboratories. This move aims to bolster IQVIA’s capabilities in early-stage drug discovery, addressing the growing demand for non-animal research methods and advanced AI platforms. The acquisition will integrate these assets with IQVIA’s existing services to create a comprehensive, end-to-end drug discovery platform.
The acquisition includes five sites specializing in in vitro drug discovery services, including New Approach Methodologies (NAMs) and a small molecule AI platform. These assets have a track record of enabling over 100 molecules to enter clinical trials and contributing to several commercially approved drugs. According to David Morris, president of IQVIA Laboratories, “This acquisition will meaningfully strengthen our ability to support clients earlier in the R&D lifecycle and complements our existing translational and clinical development capabilities.” This integration will provide pharmaceutical and biotech sponsors with a more robust suite of services from early-stage discovery through clinical development.
Key Insights at a Glance
- In Vitro Drug Discovery: The acquisition enhances IQVIA’s in vitro drug discovery capabilities.
- AI Platform: The small molecule AI platform will accelerate discovery programs.
- Non-Animal Research: The assets support growing demand for non-animal research methods.
- Therapeutic Areas: The expanded capabilities will cover Oncology, Neurology, Immunology, Metabolism, and Rare Diseases.
- Clinical Trials: Over 100 molecules have entered clinical trials due to these assets.
Why Early-Stage Discovery Research Is Critical for the Life Sciences Industry
The life sciences industry is under immense pressure to accelerate the drug discovery process. Traditional methods are often time-consuming and resource-intensive, leading to delays in bringing new treatments to market. IQVIA’s acquisition of Charles River Laboratories’ discovery services assets addresses this challenge by providing advanced in vitro and AI-driven solutions. These technologies have already enabled over 100 molecules to enter clinical trials, demonstrating their effectiveness in streamlining the discovery process. The urgency to innovate and reduce time-to-market is palpable, as patients and healthcare providers eagerly await new treatments for various diseases.
The Regulatory Clock Is Already Running for Drug Developers
Just as a marathon runner must pace themselves to finish strong, drug developers must navigate the regulatory landscape efficiently to bring their products to market. IQVIA’s expanded capabilities will help sponsors meet regulatory requirements more effectively by providing comprehensive support from early-stage discovery through clinical development. The integration of advanced in vitro methods and AI platforms will not only speed up the discovery process but also ensure that the data generated meets the high standards required by regulatory bodies. This strategic move positions IQVIA to be a key partner for pharmaceutical and biotech companies looking to stay ahead in the race to develop new treatments.
IQVIA’s Strategic Move to Create an Industry-Leading Drug Discovery Platform
IQVIA is boldly integrating the acquired assets to create a fully integrated, end-to-end drug discovery platform. This platform will span target identification, hit-to-lead, lead optimization, and early safety assessment, covering a wide range of therapeutic areas. The addition of these assets will broaden IQVIA’s ability to serve a wider range of drug modalities, including Oncology, Neurology, Immunology, Metabolism, and Rare Diseases. David Morris, president of IQVIA Laboratories, emphasized, “Integrating these assets with our existing capabilities creates an industry-leading drug discovery platform with a track record of advancing discovery programs into clinical development.” This strategic move will provide clients with a more comprehensive and efficient solution for their early-stage research needs.
Future Outlook
The life sciences industry is on the cusp of a significant transformation, driven by advancements in AI and non-animal research methods. IQVIA’s acquisition of Charles River Laboratories’ discovery services assets is a clear indication of the company’s commitment to staying at the forefront of this evolution. The transaction is expected to close in the second quarter, marking the beginning of a new era in drug discovery. As the industry continues to innovate, the integration of these advanced technologies will play a crucial role in accelerating the development of new treatments and improving patient outcomes.
Conclusion
This acquisition by IQVIA underscores the importance of integrating advanced technologies and non-animal research methods to streamline the drug discovery process. For pharmaceutical and biotech companies, this move means access to a more comprehensive and efficient platform for early-stage research. How is your organization preparing to leverage these advancements in drug discovery? Join the conversation in the comments below.
About IQVIA
IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high quality health data, Healthcare grade AI®, advanced analytics, the latest technologies, and extensive domain expertise.
IQVIA is committed to using AI responsibly, with AI powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 93,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology, and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
Source link: https://www.businesswire.com/
